Sun Pharmaceuticals Industries Ltd share Price Today

Sun Pharmaceuticals Industries Ltd. is the fourth-largest speciality generic pharmaceutical company in the world. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries worldwide. The company was founded in 1983 with its headquarters in Mumbai. For the quarter ended June 2022, Sun Pharmaceuticals Industries Ltd.’s total income was Rs HYPERLINK "https://economictimes.indiatimes.com/sun-pharmaceutical-industries-ltd/stocks/companyid-9134.cms" 10,763.90 crore, up 12.59% from the previous financial year. On 5 August 2022, the company’s market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sunpharmaceuticalindustries/SPI" 219,767 crore.  

Sun Pharmaceuticals Industries Ltd. is listed on the Bombay Stock Exchange with the code 524715. It is listed on the National Stock Exchange with the code SUNPHARMA. It is also listed on the MCX Stock Exchange. 

Sun Pharmaceuticals Industries Ltd. has more than 40 manufacturing facilities. Its product portfolio consists of generics, branded generics, over-the-counter (OTC), difficult-to-make technology-intensive products, antiretrovirals (ARVs), speciality, Active Pharmaceutical Ingredients, and its intermediates. A few flagship OTC brands of the company include Revital, Volini, and Faringosept. 

As of 30 June 2022, the company’s shareholding pattern indicated a promoter stake of 54.48%, foreign institutional investor stake of 14.95%, domestic institutional investor stake of 19.67%, and public stake of 10.91%. During the quarter ended June 2022, promoters unpledged 1.53% of shares, making the total promoter pledge stand at 4.04%. The mutual fund holdings increased from 11.63% to 11.84%, while the promoter’s holding remained unchanged. The total shares outstanding were 239.93 crores.  

The company’s chairman is Mr Israel Makov. The founder and managing director isMr Dilip Sanghvi. The North American CEO is Mr Abhay Gandhi. Ms Kirti Ganorkar is the India CEO. The other members of the top management comprise Mr Anilkumar Jain, Mr Kalyanasundaram Subramanian, Mr Sudhir V Valia, Dr Pawan Goenka, Mr Rama Bijapurkar, and Mr Gautam Doshi, among others. The auditors are SRBC & Co. LLP.  

On 5 August 2022, the share price of Sun Pharmaceuticals Industries Ltd. closed at Rs 916.35 on BSE and at Rs 915.95 on NSE. The 52-week high for Sun Pharmaceuticals Industries Ltd.’s share price was Rs 967.05, and the 52-week low for the company’s share price was Rs 733.70. 

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.